THERAPEUTIC AREA
Autoimmune Disease
INDICATIONS
IBD · SLE
DEVELOPMENT STAGE
IND-Enabling
NEXT MILESTONE
IND Submission 2027
THE PLATFORM CONNECTION
Same Biology. Different Direction.
ASD141 blocks CD11b to fight cancer. ASD001 activates CD11b to suppress autoimmune inflammation. Two therapeutic strategies from one validated biological axis.
ASD141 — ONCOLOGY
CD11b Antagonist
Blocks CD11b to release innate immune suppression and remodel the tumor microenvironment.
ASD001 — AUTOIMMUNE
CD11b Agonist
Activates CD11b to suppress dysregulated innate immune activity and restore immune homeostasis.
THE CHALLENGE
Autoimmune Disease Remains Inadequately Treated
Inflammatory bowel disease (IBD) and systemic lupus erythematosus (SLE) are driven by dysregulated innate immune activity — yet most existing therapies broadly suppress the immune system, leading to serious side effects and incomplete disease control.
A targeted approach that restores immune homeostasis — rather than blanket suppression — represents a significant unmet need.
PRECLINICAL EVIDENCE
Efficacy Comparable to Infliximab in IBD Model
In a DSS-induced IBD mouse study, ASD001 markedly attenuated colonic fibrosis and histopathological damage — demonstrating efficacy comparable to infliximab, a current standard of care.
VEHICLE (CONTROL)
HS: 16.8
Histopathological Score ±3.3
FS: 15.4
Fibrosis Score ±4.1
ASD001
HS: 11.3
Histopathological Score ±8.5
FS: 12.3
Fibrosis Score ±1.2
INFLIXIMAB (SOC)
HS: 20.0
Histopathological Score ±2.2
FS: 12.1
Fibrosis Score ±4.9
ASD001 achieved fibrosis scores comparable to infliximab (FS 12.3 vs 12.1), with significantly lower histopathological damage than vehicle control.
DEVELOPMENT ROADMAP
Path to the Clinic
ASD001 has an optimized lead candidate and is currently advancing through IND-enabling studies ahead of first-in-human trials.
CURRENT STATUS
IND-Enabling Stage
Optimized lead candidate selected
2027
IND Submission
Regulatory filing planned
2027
Phase I Initiation
First-in-human study upcoming
INDICATIONS
IBD · SLE
Two commercially distinct markets
Ready to Explore a Partnership?
Our business development team is available for confidential discussions on licensing, co-development, and investment opportunities.